Denis Andreev

List of Publications by Year
in descending order

35 papers	239 citations	1307594 7 h-index	996975 15 g-index
41 all docs	41 docs citations	41 times ranked	242 citing authors

#	Article	IF	Citations
1	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology, 2021, 26, 4594.	1.4	89
2	Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 43-49.	0.7	24
3	Interval training early after heart failure decompensation is safe and improves exercise tolerance and quality of life in selected patients. European Journal of Preventive Cardiology, 2018, 25, 9-18.	1.8	17
4	EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2015, 11, 85-91.	0.8	11
5	A new algorithm for optimization of rateâ€adaptive pacing improves exercise tolerance in patients with HFpEF. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 223-233.	1.2	10
6	CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 29-37.	0.7	10
7	The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy, 2018, 33, 109-118.	0.6	7
8	Comparison of the Efficacy of Neuromuscular Electrostimulation and Interval Exercise Training in Early Rehabilitation of Patients Hospitalized with Decompensation of Chronic Heart Failure. Human Physiology, 2018, 44, 663-672.	0.4	5
9	Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metabolism and Personalized Therapy, 2019, 34, .	0.6	5
10	Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?. Pharmacogenomics and Personalized Medicine, 2017, Volume 10, 243-245.	0.7	4
11	THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE. Rational Pharmacotherapy in Cardiology, 2013, 9, 404-408.	0.8	3
12	THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE. Rational Pharmacotherapy in Cardiology, 2016, 12, 253-259.	0.8	3
13	Genotyping and phenotyping CYP3A4CYP3A5: no association with antiplatelet effect of clopidogrel. Molecular Biology Reports, 2019, 46, 4195-4199.	2.3	3
14	Silent hypoxemia in a patient with severe SARS-CoV-2 pneumonia. SeÄenovskij Vestnik, 2020, 11, 87-91.	0.4	3
15	New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants. Rational Pharmacotherapy in Cardiology, 2020, 16, 670-677.	0.8	3
16	MicroRNAs as Novel Biomarkers for P2Y12 â€“ Inhibitors Resistance Prediction. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1575-1582.	0.7	3
17	Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation. Pharmacology, 2022, 107, 216-226.	2.2	3
18	Pheno- and genotyping the prescription of drugs metabolized by CYP2D6. Bulletin of Experimental Biology and Medicine, 2002, 134, 159-160.	0.8	2

#	Article	IF	Citations
19	EMBOLIC MYOCARDIAL INFARCTION. EXPERIENCE IN DIAGNOSIS AND MANAGEMENT. Rational Pharmacotherapy in Cardiology, 2018, 14, 361-369.	0.8	2
20	The Use of â€œSpaceâ€•Electrical Myostimulation in Clinical Cardiology on Earth. Human Physiology, 2021, 47, 382-390.	0.4	2
21	GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA. Russian Journal of Cardiology, 2015, , 92.	1.4	2
22	Mental Disorder in Chronic Heart Failure. Psychiatry, 2021, 19, 109-124.	0.7	2
23	Prognostic Value of Seattle Heart Failure Model in Chronic Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2017, 23, S76-S77.	1.7	1
24	DIAGNOSTICS OF ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE CARDIAC ELECTRONIC DEVICES: PREVALENCE AND RISK FACTORS. Russian Journal of Cardiology, 2017, , 62-67.	1.4	1
25	THE USE OF ATORVASTATIN FOR THE PREVENTION OF RECURRENT ATRIAL FIBRILLATION AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology, 2010, 6, 657-661.	0.8	0
26	Preparation and characterization of monoclonal antibodies to human adiponectin for its quantitative measurement in serum. Applied Biochemistry and Microbiology, 2012, 48, 691-698.	0.9	0
27	INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. Rational Pharmacotherapy in Cardiology, 2015, 11, 344-354.	0.8	0
28	Long-Term Follow-Up of Chronic Heart Failure Patients Presenting with Exercise Oscillatory Ventilation. Journal of Cardiac Failure, 2016, 22, S77.	1.7	0
29	Prognostic Value of Post-exercise Oxygen Uptake Kinetics in Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure, 2018, 24, S35.	1.7	0
30	P2907The new warfarin dosing algorithm for patients with atrial fibrillation and severe chronic kidney disease. European Heart Journal, 2018, 39, .	2.2	0
31	NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME. Rational Pharmacotherapy in Cardiology, 2018, 14, 47-52.	0.8	0
32	Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran. Rational Pharmacotherapy in Cardiology, 2021, 17, 186-192.	0.8	0
33	Direct oral anticoagulants for electrical cardioversion. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2932.	1.4	0
34	Anticoagulant therapy in catheter ablation of atrial fibrillation and flutter. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2974.	1.4	0
35	Anticoagulants for subclinical atrial fibrillation. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2019, 12, 441.	0.3	0